Please login to the form below

Not currently logged in
Email:
Password:

Dutch biotech Mucosis promotes Thomas Johnston to CEO

He succeeds Govert Schouten who leaves to found an internet start-up

Dutch biotech Mucosis Thomas JohnstonThomas Johnston has been promoted to CEO of Mucosis to take over from Govert Schouten, who is leaving the Dutch clinical-stage biotech to found an internet start-up.

Johnston joined Mucosis last May as chief business officer from the clinical biopharmaceutical company Novavax, where he served as vice president of strategy.

Prior to that he served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with companies such as Comcast, Microsoft, and Schlumberger.

John Lambert, chairman of the Mucosis board of directors, said: "Tom has more than 15 years of leadership experience in the biotech and other industries and has been an invaluable member of our executive management team.

“Given Tom's substantial commercial experience and familiarity with the Company, we are confident he is the right person to lead Mucosis as we execute our strategy and further advance the development and commercialisation of the Mimopath platform including our RSV vaccine candidate."

During the last 12 months Mucosis has completed a clinical proof of concept study in human influenza for Mimopath and advanced respiratory syncytial virus (RSV) candidate SynGEM into pre-clinical studies.

19th September 2012

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...